September 9, 2019 / 11:52 AM / 9 days ago

BRIEF-Kahr Medical Announces New Clinical Collaboration With Roche

Sept 9 (Reuters) - Kahr Medical:

* KAHR MEDICAL ANNOUNCES CLINICAL TRIAL COLLABORATION TO EVALUATE DSP107 IN COMBINATION WITH A PD-L1 CHECKPOINT INHIBITOR IN ADVANCED LUNG CANCER PATIENTS

* KAHR MEDICAL- PATIENT ENROLMENT EXPECTED TO COMMENCE IN H1 2020

* KAHR MEDICAL - ANNOUNCED NEW CLINICAL COLLABORATION WITH ROCHE

* KAHR MEDICAL - COLLABORATION WITH ROCHE WILL EVALUATE POTENTIAL OF DSP107 & ATEZOLIZUMAB IN NSCLC PATIENTS WHO ARE REFRACTORY TO PD1/PD-L1 INHIBITORS

* KAHR MEDICAL- EXPECTS TO FILE AN IND APPLICATION WITH U.S. FDA IN H1 2020

* KAHR MEDICAL - EXPECTS TO BEGIN PHASE I/II TRIAL IN H1 2020 TO EVALUATE DSP107 AS A MONOTHERAPY AND IN COMBINATION WITH ATEZOLIZUMAB Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below